DUBLIN--(BUSINESS WIRE)--The "United States Specialty Pharmaceuticals Market & Forecast by Application (Oncology, Autoimmune, Immunology, HIV, Multiple Sclerosis, Hematology, AMD, HGH, Others), and Companies" report has been added to ResearchAndMarkets.com's offering.
It is expected that United States Specialty Pharmaceutical Market will be US$ 387 Billion by 2026.
In the United States, the Pharmaceutical market can be categorized into two types of drugs: Traditional as well as Specialty drugs. In recent times, Specialty drugs have gained a substantial foothold in the US market, and as estimated, it tends to gain more momentum in the upcoming years. For this, the credit goes to the companies' initiatives towards Research and Developments (R&D's) of these drugs.
During the years, Specialty pharmaceutical has changed much due to specialty drugs being in the final stages of development in the United States. Specialty drugs are for rare and chronic diseases, and the drugs falling under this category are much expensive compared to traditional medications. Research has shown that a large portion of the US population is ageing and more people are prone towards chronic and rare diseases like cancer, Autoimmune, Multiple sclerosis.
In the year 2018, the FDA has approved 21 new molecular entities. Out of these products, 12 are regarded as specialty pharmaceutical based on variables such as indication and designed use population, administrative and tracking considerations, price and restricted delivery procedures. Dating back five years, spending on specialty drugs has almost doubled in the United States.
An ageing population, rise in the net per capita medicine spending on specialty drugs, improving life expectancy rate, the prevalence of chronic diseases are likely to boost the United States Specialty pharmaceuticals market at a staggering rate in upcoming years.
All the 9 Diseases have been studied from two points
- Market
- Drugs Pipeline
Application - The Report Covers the Market, Drugs Pipelines of 9 diseases
1. Oncology
2. Autoimmune
3. Immunology
4. HIV
5. Multiple Sclerosis
6. Hematology
7. Age-related macular degeneration (AMD)
8. Human Growth Hormones (HGH)
9. Others
All the key players have been covered from 3 Viewpoints
- Overview
- Recent Developments
- Revenue Analysis
Company Analysis
- CVS Health
- Endo International
- UnitedHealth Group Incorporated
- Recordati Pharmaceuticals
For more information about this report visit https://www.researchandmarkets.com/r/wg3k2d
